Skip to main content
Skip to navigation

All PAPZIMEOS articles

News
Precigen presents new long-term durability data for PAPZIMEOS, recently granted seven-year market exclusivity

2026-06-02T09:15:00Z

Precigen, Inc. has announced updated long-term follow-up data from the pivotal study of PAPZIMEOS™ (zopapogene imadenovec-drba) for the treatment of adults with recurrent respiratory papillomatosis (RRP).